Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets
Authors:
Open Access
- 1 June 2018
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 4 (5) , 500-505
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Successful Treatment of Refractory Pityriasis Rubra Pilaris With SecukinumabJAMA Dermatology, 2016
- Response of persistent juvenile pityriasis rubra pilaris to secukinumabJournal of the American Academy of Dermatology, 2016
- Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation inCARD14British Journal of Dermatology, 2014
- Consider triggers for pityriasis rubra pilarisClinical and Experimental Dermatology, 2014
- Effectiveness of Infliximab in Pityriasis Rubra Pilaris Is Associated with Pro-Inflammatory Cytokine InhibitionDermatology, 2013
- A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF‐antagonistsJournal of the European Academy of Dermatology and Venereology, 2012
- A Framework and Standardized Methodology for Developing Minimum Clinical Datasets2011
- Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case seriesJournal of the European Academy of Dermatology and Venereology, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Pityriasis rubra pilaris*Clinical and Experimental Dermatology, 1980